Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 1997-2003

  Still, J Gordon ^a   Schranz, Jennifer ^a   Degenhardt, Thorsten P ^a   Scott, Drusilla ^a   Fernandes, Prabhavathi ^a   Gutierrez, Maria J ^b   Clark, Kay ^a  

^a Cempra Pharmaceuticals   (United States)

^b Comprehensive Phase One ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEM 101; KETOLIDE; SOLITHROMYCIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; LIPID DIET; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; DOUBLE-BLIND METHOD; FASTING; FEMALE; HUMANS; MACROLIDES; MALE; MIDDLE AGED; TRIAZOLES; YOUNG ADULT;

EID: 79955542813     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01429-10     Document Type: Article

References (43)

1. Bartlett, J. G., et al. 1998. Community-acquired pneumonia in adults; guidelines for management. Clin. Infect. Dis. 26:811-838.
2. Berisio, R., et al. 2003. Structural insight into the antibiotic action of telithromycin against resistant mutants. J. Bacteriol. 185:4276-4279. (Pubitemid 36835269)
3. Bertrand, D., S. Bertrand, E. Neveu, and P. Fernandes. 2010. Molecular characterization of off-target activities of telithromycin: a potential role of nicotinic acetylcholine receptors. Antimicrob. Agents Chemother. 54:5399-5402.
4. Biedenbach, D. J., L. M. Deshpande, T. R. Fritsche, H. S. Sader, and R. N. Jones. 2008. Antimicrobial characterization of CEM-101: activity against enterococci, uncommon Gram-positive pathogens, N. gonorrhoeae and anaerobes, abstr. F1-3976. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
5. Clark, C., K. Kowasaka-Shick, P. McGhee, K. Nagai, and P. Appelbaum. 2009. Capability of CEM-101 to select for resistant pneumococcal and group A streptococcal clones by multistep resistance selection, abstr. F1-2039. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
6. Clay, K. D., et al. 2006. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann. Intern. Med. 144: 415-420.
7. Craft, J. C., S. Wittlin, J. Lotharius, I. Bathurst, and P. Fernandes. 2010. Solithromycin (CEM-101) - a new fluoroketolide with antimalarial activity, abstr. 269. Abstr. 59th Annu. Meet. Am. Soc. Trop. Med. Hyg. American Society of Tropical Medicine and Hygiene, Deerfield, IL.
8. Craig, W. A., S. Kiem, and D. R. Andes. 2002. PK/PD target correlates with in vivo efficacy of macrolides, azilides, ketolides and clindamycin, abstr. A-1264. Abstr. 42nd Intersci. Conf. Antmicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
9. Dubois, J., and P. Fernandes. 2009. In vitro activity of CEM-101 against Legionella spp., abstr. F1-2036. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
10. Dubois, J., and P. Fernandes. 2009. In vitro activity of CEM-101 against resistant strains of Staphylococcus aureus, abstr. F1-2037. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
11. Farrell, D. J., et al. 2010. Antimicrobial characterization of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. Int. J. Antimicrob. Agents 45:537-543.
12. Farrell, D. J., M. Castanheira, H. S. Sader, and R. N. Jones. 2010. The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009). J. Infect. 61:476-483.
13. Felmingham, D. 2002. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin. J. Infect. 44(Suppl. A):3-10.
14. Heine, H. S., L. Miller, J. Bassett, and K. Holman. 2008. Antimicrobial activity of CEM-101 a new macrolide, tested against diverse collections of bacterial biowarfare/bioterrorism agents, abstr. F1-3980. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
15. Jones, R. N., H. S. Sader, and D. J. Biedenbach. 2009. Antimicrobial characterization of CEM-101: activity against staphylococci, β-haemolytic and viridans group streptococci, abstr. P-1100. Abstr. 19th Eur. Congr. Clin. Microbiol. Infect. Dis.
16. Reference deleted.
17. Jones, R. N., L. N. Woosley, G. J. Moet, and P. R. Rhomberg. 2009. Activity of CEM-101 tested against emerging telithromycin-resistant β-haemolytic streptococci, abstr. P-1101. Abstr. 19th Eur. Congr. Clin. Microbiol. Infect. Dis.
18. Jones, R. N., M. G. Stilwell, H. S. Sader, and P. Fernandes. 2009. CEM- 101, a novel fluoroketolide: activity against recent (2008) isolates of multidrug-resistant S. pneumoniae, abstr. 208. Abstr. 47th Annu. Meet. Infect. Dis. Soc. Am.
19. Jones, R. N., P. R. Rhomberg, and H. S. Sader. 2008. Antimicrobial characterization of CEM-101: single step, selection by passaging and inducible resistances, abstr. F1-3982. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
20. Lemaire, S., F. Van Bambeke, and P. M. Tulkens. 2009. Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM- 101, a novel fluoroketolide against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. Antimicrob. Agents Chemother. 53:3734-3743.
21. Li, X., et al. 2009. Emerging macrolides resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates. Pediatr. Infect. Dis. J. 28:693-696.
22. Lismond, A., F. Van Bambeke, and P. M. Tulkens. 2009. Comparative activities of the novel ketolide CEM-101 and telithromycin (TEL) towards Streptococcus pneumoniae (SP) resistant to macrolides (ML) from patients with confirmed community-acquired pneumonia (CAP), abstr. P-1099. Abstr. 19th Eur. Congr. Clin. Microbiol. Infect. Dis.
23. Mandell, L. A., et al. 2003. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. 37:1405-1433.
24. McGhee, P., et al. 2010. In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. Antimicrob. Agents Chemother. 54:230-238.
25. McGuire, J. M., P. L. Bunch, and R. C. Anderson. 1952. Ilotycin, a new antibiotic. Antibiot. Chemother. 2:281-283.
26. Murphy, T. M., et al. 2009. Efficacy and pharmacodynamic evaluation of CEM-101, a novel macrolide, in murine infection models, abstr. P-1098. Abstr. 19th Eur. Congr. Clin. Microbiol. Infect. Dis.
27. Murphy, T. M., S. Little, A. M. Slee, and P. Fernandes. 2010. Evaluation of solithromycin (CEM-101), a novel fluoroketolide, in murine infection models, abstr. F1-2152. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
28. Murphy, T. M., S. Little, R. Wu, A. M. Slee, and P. Fernandes. 2009. Evaluation of CEM-101, a novel fluoroketolide, in a rat H. influenzae pulmonary infection model, abstr. F1-2040. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
29. Neiderman, M. S. 2005. Principles of appropriate antibiotic use. Int. J. Antimicrob. Agents 26(Suppl. 3):S170-S175.
30. Putnam, S. D., M. Castanheira, G. J. Moet, D. J. Farrell, and R. N. Jones. 2010. CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. Diagn. Microbiol. Infect. Dis. 66:393-401.
31. Robin, P. M., S. A. Kohlhoff, C. Parker, and M. R. Hammerschlag. 2010. In vitro activity of CEM-101, a new ketolide antibiotic against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob. Agents Chemother. 54: 1358-1359.
32. Rodvold, K. A., et al. 2010. Intrapulmonary penetration of CEM-101 in healthy adult subjects, abstr. A1-690. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
33. Ross, D. B. 2007. The FDA and the case of Ketek. N. Engl. J. Med. 356: 1601-1604.
34. Sader, H. S., D. L. Biedenbach, P. R. Rhomberg, and R. N. Jones. 2008. Antimicrobial characterization of CEM-101: PAE, bactericidal activity and combinations, abstr. F1-3981. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
35. Schranz, J., et al. 2010. Phase 1 pharmacokinetic and safety of multiple doses and effects of food on the bioavailability of oral solithromycin (CEM-101) in healthy adult subjects, abstr. A1-689. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
36. Shain, C. S., and G. W. Amsden. 2002. Telithromycin: the first of the ketolides. Ann. Pharm. 36:452-464.
37. Shi, J., G. Montay, and V. O. Bhargava. 2006. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin. Pharmacokinet. 44:915-934.
38. Still, J. G., K. Clark, T. Degenhardt, D. Scott, and P. Fernandes. 2010. Multiple dose pharmacokinetics and safety of CEM-101, a new fluoroketolide, in healthy subjects, abstr. 902. Abstr. 20th Eur. Congr. Clin. Microbiol. Infect. Dis.
39. BK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell 121:257-270.
40. Waites, K. B., D. M. Crabb, and L. B. Duffy. 2009. Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. Antimicrob. Agents Chemother. 53:2139-2141.
41. Wierzbowski, A. K. K., et al. 2007. Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998-2004). J. Antimicrob. Chemother. 60:733-740.
42. WMADH. 2000. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 20:3043-3045.
43. Woosley, L. N., M. Castanheira, and R. N. Jones. 2010. Characterization of CEM-101 activity against gram-positive organisms. Antimicrob. Agents Chemother. 54:2182-2187.